FAHA

Largest real-world study finds tirzepatide (Mounjaro) up to three times more effective than semaglutide (Ozempic) for weight loss

Retrieved on: 
Lunedì, Novembre 27, 2023
EHR, Providence Portland Medical Center, SDOH, Semaglutide, Overweight, Physician, FDA, Weight loss, Paper, FACC, Health, MD, Doctor of Philosophy, Education, Prescription, University Challenge 2013–14, MHA, Type 2 diabetes, Obesity, FAHA, CARDS, Patient, Human, Data science, Infection, Female, GIP, Pharmaceutical industry

In this study, Truveta Research explored weight loss trends for patients taking semaglutide and tirzepatide approved by the FDA for treating type 2 diabetes (Ozempic and Mounjaro, respectively).

Key Points: 
  • In this study, Truveta Research explored weight loss trends for patients taking semaglutide and tirzepatide approved by the FDA for treating type 2 diabetes (Ozempic and Mounjaro, respectively).
  • The study found that in the initial unadjusted population, those taking tirzepatide and semaglutide differed.
  • The analysis found that patients taking tirzepatide were significantly more likely to achieve weight loss:
    Those taking tirzepatide were 1.8 times more likely than those taking semaglutide to achieve 5% weight loss,
    2.6 times more likely than those taking semaglutide to achieve 10% weight loss,
    And three times more likely than those taking semaglutide to achieve 15% weight loss.
  • At six months, the mean percentage change in body weight was -10.1% for those taking tirzepatide versus -5.9% for those taking semaglutide.

Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023

Retrieved on: 
Lunedì, Novembre 13, 2023
Disease, Esperion Therapeutics, Rash, Abdominal pain, AHA, Membrane protein, Patient, Bempedoic acid, PCSK9, CVD, Anemia, Angioedema, Rupture, Inflammation, Diet, Atherosclerosis, Safety, Incidence, FAHA, Mortality, Tablet, Health, Tendon rupture, Diarrhea, Harvard Medical School, Ezetimibe, Urinary tract infection, Fetus, Hypersensitivity, Arthralgia, Gout, American Heart Association, ESPR, Therapy, Sinusitis, Risk, Spasm, Constipation, MACE, Anaphylaxis, Pain, Moyamoya disease, Back pain, Upper respiratory tract infection, FACC, Flexner Report, CLEAR, Fatigue, Pregnancy, Kidney, Uric acid, MPH, ATP, Bronchitis, Hospital, Dietary supplement, Pharmaceutical industry, Vaccine, Common, Esperies, Brigham, Hyperuricemia, MD, Cholesterol

ANN ARBOR, Mich., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of results from a pre-specified, exploratory analysis of CLEAR Outcomes at the 2023 American Heart Association (AHA) Scientific Sessions. Results were also simultaneously published in Circulation which can be accessed here.

Key Points: 
  • “In the future, it can be anticipated that virtually all atherosclerosis patients will receive aggressive inflammation inhibition along with aggressive cholesterol reduction,” Ridker added.
  • In CLEAR Outcomes, patients who were randomized to bempedoic acid experienced a 21.6% reduction in hsCRP compared to placebo at 6 months.
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

BCV Raises €6M Series A

Retrieved on: 
Mercoledì, Dicembre 13, 2023
Research, General Health, Professional Services, Medical Devices, Technology, Other Professional Services, Clinical Trials, Science, Biotechnology, Finance, Other Technology, Health, Peripheral artery disease, Safety, FAHA, NTI, Multimedia, Partner, FDA, FACS, CE, Stroke, Miniaturization, Lead, MD, Doctor of Philosophy, Gesture, BCV, Reims

This Series A funding brings the total amount raised since inception to €13M.

Key Points: 
  • This Series A funding brings the total amount raised since inception to €13M.
  • “Our technology, applied to a guidewire, will be a disruptive change in minimally invasive procedures improving patients’ outcomes,” says Raphaël Blanc, M.D., Chairman & Co-Founder, BCV.
  • “This round of financing will enable BCV to progress toward FDA and CE mark approval,” adds Thierry Col, CEO, BCV.
  • The BCV system’s shape-memory alloy technology enables distal tip control improving practitioners’ gestures and demonstrating superior performance over existing advanced actuation technologies.

Cardiawave Announces the Publication in The Lancet of First-In-Human Clinical Studies Results With 40 Aortic Stenosis Patients Treated With Its Innovative Non-invasive Ultrasound Therapy (NIUT)

Retrieved on: 
Mercoledì, Novembre 15, 2023
Research, Medical Devices, Clinical Trials, Cardiology, Biotechnology, Other Health, Radiology, Health, Science, FACP, Food, Treatment, Medtech, FAHA, AP-HP, FACC, CAS, Mortality, FCCP, Patient, FIH, Ultrasound, FDA, CE, MD, Trial of the century, FESC, Doctor of Philosophy, Quality of life, Medical device, Pharmaceutical industry, Lancet

The patients were treated with Cardiawave’s NIUT investigational device in one session.

Key Points: 
  • The patients were treated with Cardiawave’s NIUT investigational device in one session.
  • “Clinically, the patients experienced a considerable improvement in their clinical status suggesting a better quality of life.
  • These early findings can represent a change in the paradigm of CAS treatment especially for patients who have no other options.
  • In July 2023, Cardiawave successfully completed the patient enrolment with no procedure or device-related mortality up to 30 days.

Cleerly, Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023

Retrieved on: 
Sabato, Novembre 11, 2023
Health, Technology, Health Technology, Clinical Trials, Artificial Intelligence, Pharmaceutical, Cardiology, Esperion Therapeutics, Participation, Ezetimibe, Atherosclerosis, Therapy, FAHA, Plaque, FACC, AHA, Cholesterol, Risk, CCTA, Cardiovascular disease, CAD, Tablet, Patient, Myocardial infarction, Bempedoic acid, Molina Healthcare, LDL, Type 2 diabetes, American Heart Association, University, Diagnosis, Pulmonary Vascular Research Institute, MPH, FESC, Splenic infarction, ASCVD, AI, Metabolic syndrome, Prediabetes, American Heart, Moyamoya disease, Pharmaceutical industry, Dietary supplement, Management, Medical imaging, Medicine, MD

Cleerly , the company working to create a new standard of care for the diagnosis of heart disease, today announced the TRANSFORM trial at the American Heart Association’s (AHA) 2023 Scientific Sessions.

Key Points: 
  • Cleerly , the company working to create a new standard of care for the diagnosis of heart disease, today announced the TRANSFORM trial at the American Heart Association’s (AHA) 2023 Scientific Sessions.
  • TRANSFORM is a randomized trial – sponsored by Cleerly – that aims to enroll 7,500 patients who have pre-diabetes, type 2 diabetes, or metabolic syndrome and have no symptoms of heart disease.
  • TRANSFORM aims to prove that a personalized care strategy based on a Cleerly analysis is better than usual care based on traditional cardiovascular risk factors for the primary prevention of cardiovascular events.
  • “This trial provides us the opportunity to revolutionize cardiovascular event prevention and ultimately save lives from heart disease.

Wolters Kluwer unveils Lippincott Partnership, a complete nursing education curriculum solution ushering in a new era of student learning

Retrieved on: 
Giovedì, Novembre 9, 2023
Education, Health, General Health, Other Education, Continuing, University, Training, Faculty, Wolters Kluwer, Health care, Heart, FAHA, Workforce, RN, Acquisition, Doctor of Philosophy, Accreditation, Multimedia, Digital technology, NCLEX, American Association of Colleges of Nursing, Information technology, Curriculum, Student, Education minister, Lippincott, School, FAAN, Nursing

With the integration of NurseTim® / NurseThink® now complete, Wolters Kluwer provides a full curriculum suite of educational products and services for the nation’s leading prelicensure nursing programs.

Key Points: 
  • With the integration of NurseTim® / NurseThink® now complete, Wolters Kluwer provides a full curriculum suite of educational products and services for the nation’s leading prelicensure nursing programs.
  • View the full release here: https://www.businesswire.com/news/home/20231109392068/en/
    Lippincott Partnership for Nursing Education and Testing empowers nursing schools to graduate safe, competent, practice-ready nurses while supporting faculty workflows.
  • This new offer creates a cost-effective way for nursing schools to ensure complete curriculum coverage that is essential for accreditation.
  • Lippincott Partnership for Nursing Education and Testing also equips colleges and universities with turn-key resources to help today’s nursing students prepare for the next-generation NCLEX, while sustaining student retention and satisfaction levels.

Reperio Health Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation

Retrieved on: 
Giovedì, Novembre 2, 2023
Software, General Health, Telemedicine, Virtual Medicine, Biometrics, Apps, Applications, Medical Devices, Technology, Health Technology, Health Insurance, Cardiology, Practice Management, Health, Science, FAHA, American Heart Association, Organization, American Heart, Cornell University, Patient, Weill Cornell Medicine, Pharmaceutical industry

Reperio Health , the only provider of at-home and onsite comprehensive health screenings with instant results, has joined the American Heart Association Center for Health Technology & Innovation’s (the Center) Innovators’ Network.

Key Points: 
  • Reperio Health , the only provider of at-home and onsite comprehensive health screenings with instant results, has joined the American Heart Association Center for Health Technology & Innovation’s (the Center) Innovators’ Network.
  • The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.
  • The Innovators’ Network is a health care technology consortium that connects entrepreneurs, providers, researchers and payers.
  • “We look forward to continued participation with the American Heart Association, its Innovators’ Network and other key stakeholders in the collective effort towards improving outcomes for patients, providers, and payers alike.”

Aktivolabs joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation

Retrieved on: 
Mercoledì, Novembre 1, 2023
Managed Care, Software, Other Health, General Health, Mobile, Wireless, Professional Services, Apps, Applications, Technology, Other Professional Services, Cardiology, Insurance, Other Technology, Health, Science, FAHA, HIPAA, American Heart Association, Entrepreneurship, Multimedia, Bangalore, American Heart, AXA, Collaborative innovation network, Sleep, Cornell University, Series, Weill Cornell Medicine, Sun Life Financial, Pharmaceutical industry, Innovation

Aktivolabs, a digital health science company on a mission to prevent chronic diseases globally, announced today it has joined the American Heart Association Center for Health Technology & Innovation (the Center) Innovators’ Network.

Key Points: 
  • Aktivolabs, a digital health science company on a mission to prevent chronic diseases globally, announced today it has joined the American Heart Association Center for Health Technology & Innovation (the Center) Innovators’ Network.
  • The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.
  • View the full release here: https://www.businesswire.com/news/home/20231101510432/en/
    Aktivolabs has become a member of the American Heart Association Center for Health Technology and Innovation called the Innovators Network.
  • “Joining the Innovators’ Network gives members the opportunity to leverage the consortium and work toward broadening and deepening their engagement in this arena.”
    “Akitvolabs is honored to be a Digital Health Science company within the American Heart Association Center for Health Technology and Innovation,” says Gourab Mukherjee, Co-Founder and CEO of Aktivolabs.

Toku joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation

Retrieved on: 
Lunedì, Ottobre 30, 2023
Cardiology, Entrepreneur, Technology, Health, Optical, Health Technology, Other Science, Software, Artificial Intelligence, Consumer, Science, Inc., FAHA, American Heart Association, American Heart, Cornell University, Patient, Weill Cornell Medicine, Associate, Pharmaceutical industry

Toku Inc, a provider of an AI-based screening tool for detection of cardiovascular risk through retinal imaging, has joined the American Heart Association Center for Health Technology & Innovation’s (the Center) Innovators’ Network.

Key Points: 
  • Toku Inc, a provider of an AI-based screening tool for detection of cardiovascular risk through retinal imaging, has joined the American Heart Association Center for Health Technology & Innovation’s (the Center) Innovators’ Network.
  • The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.
  • The Innovators’ Network is a health care technology consortium that connects entrepreneurs, providers, researchers, and payers.
  • Innovators’ Network members also have access to the Association’s digital guidelines, recommendations, and best-in-class science as they develop digital healthcare technologies.

Evident Vascular Announces Scientific Advisory Board and New Board Member

Retrieved on: 
Lunedì, Ottobre 30, 2023
Health, Technology, Health Technology, Artificial Intelligence, Cardiology, Biotechnology, Yee, Intelligence, Faculty, FAHA, JD, FSVM, FACC, Manatee Memorial Hospital, LLP, RPVI, Workflow, Master of Science, VIVA, IVUS, Patient, CPO, Diagnosis, Scientific Committee on Emerging and Newly Identified Health Risks, Evidence, MS, Coronavirus Scientific Advisory Board, Management, Medical imaging, MD

Evident Vascular, Inc. a medical technology startup developing a next-generation intravascular ultrasound (IVUS) platform leveraging artificial intelligence to enable superior imaging and streamlined workflows, announced today its Scientific Advisory Board and expansion of its Board of Directors.

Key Points: 
  • Evident Vascular, Inc. a medical technology startup developing a next-generation intravascular ultrasound (IVUS) platform leveraging artificial intelligence to enable superior imaging and streamlined workflows, announced today its Scientific Advisory Board and expansion of its Board of Directors.
  • “It is our privilege to have this esteemed group of clinical experts on our Scientific Advisory Board.
  • “We are also pleased to welcome Bruce Shook to the Evident Vascular Board of Directors.
  • Evident Vascular is developing the first IVUS platform designed for peripheral interventions, with enhanced ease of use and improved image quality.